SDI Reports: amid Swine Flu Fears, New Antiviral Prescriptions Increase over 19 Times in 1 Week
Nearly Twice as High as During 2008 – 2009 Peak Flu Season
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--May 5, 2009 - SDI's Vector One®: National shows that for the week ending May 1, the number of new antiviral prescriptions dispensed at retail pharmacies was 277,196 — over 19 times higher than the prior week.
The number of new antiviral prescriptions last week was nearly double that of new antiviral prescriptions during the peak of the 2008-2009 flu season. According to SDI's Sentinel Laboratory Network, which monitors circulating strains of influenza by tracking influenza type, location, and patient age groups infected, the peak of this most recent flu season was during the week of March 7. The weeks before and after showed new prescriptions ranging from approximately 150,000 to a high of nearly 155,000 during the week ending Feb. 27.
| VONA® New Antiviral Prescriptions | |||||||||||||||||
| Peak Weeks 2008-2009 Flu Season | Two Most Recent Weeks | ||||||||||||||||
| Week
ending 2/13/09
|
Week
ending 2/20/09
|
Week
ending 2/27/09
|
Week
ending 3/6/09
|
Week
ending 3/13/09
|
Week
ending 3/20/09
|
Week
ending 4/24/09
|
Week
ending 5/1/09
|
||||||||||
| TOTAL MARKET | 150,645 | 136,555 | 154,673 | 151,159 | 128,180 | 89,684 | 14,366 | 277,196 | |||||||||
| Relenza | 19,298 | 18,718 | 23,797 | 25,591 | 22,231 | 14,520 | 1,349 | 13,591 | |||||||||
| Tamiflu | 109,230 | 95,978 | 107,744 | 100,840 | 85,505 | 59,806 | 7,422 | 254,326 | |||||||||
| All others* | 22,117 | 21,859 | 23,132 | 24,728 | 20,444 | 15,358 | 5,595 | 9,279 | |||||||||
| *Amantadine, Rimantadine
|
|||||||||||||||||
Vector One®: National offers the fastest weekly projections available in the industry.
About SDI
Since 1982, SDI has been delivering innovative healthcare data products and analytic services to the pharmaceutical, biotech, healthcare, medical device, financial services, and consumer packaged goods industries. SDI is the leading provider of de-identified patient-level data analytics and offers a broad array of solutions and insights across the continuum of care. These include custom and syndicated patient-level data studies; localized disease and treatment surveillance and projection; market research audits; healthcare profiles; comprehensive managed care offerings; clinical trial optimization; direct-to-patient pharmacy programs; marketing effectiveness; sales targeting and compensation products; data integration, warehousing, and mining; list services; and direct marketing services. Its current roster includes the top 50 pharmaceutical/biotech companies. For more information, visit www.sdihealth.com or call 610.834.0800.
Contact: SDI
Tracy Everly, 267-685-4387
teverly@sdihealth.com
or
Buchanan Public Relations
Shannon Bernauer, 610-649.9292
shannon@buchananpr.com
Posted: May 2009
